Non-invasive Gas Jet In-Vivo Profile Dosimetry for Particle Beam Therapy (JetDose)

在强子束治疗中，详细的束属性的知识是必不可少的，以确保有效的剂量输送到病人。临床环境目前实施拦截电离室，其需要每日校准并且遭受缓慢的响应时间。随着使用超高剂量率的新的和新兴的治疗技术，需要开发快速、非侵入性和免校准的新型射束监测器。目前进行这种表征的方法需要多个系统，每个系统在粒子束经过时对粒子束施加轻微的扰动。这种干扰可以改变射束的预期横向剂量分布，最终产生与患者治疗计划的轻微偏差。质量保证方法大多是破坏性的测量，不允许治疗发生在所有，而他们正在进行。JetDose将开发一个新的体内剂量系统的基础上重新应用的技术开创了由提案人的小组。支撑技术最初是为低能反质子束而开发的，最近被用于欧洲核子研究中心大型强子对撞机高亮度升级的气体射流剖面。在这个系统中，超音速气体射流被发射到LHC的高强度质子束上。气体分子对质子束几乎没有影响，但是质子束激发气体分子;这种激发可以成像，这反过来又提供了质子束的完整的非侵入性二维轮廓图像。JetDose将在医疗加速器领域重新引导这项技术，针对治疗设施中的不同挑战进行优化。生成轮廓图像的非侵入性方法将允许监视器与治疗操作一起在线运行。由于图像中的强度直接取决于射束强度，因此也就取决于剂量，因此，使用该系统采集的图像提供了射束输送到患者的体内剂量图。该项目的重点将是与已建立的临床和商业合作伙伴一起设计、开发和测试该系统的优化医疗版本。测试和优化将与长期研究合作伙伴Clatterbridge癌症中心和意大利的CNAO基金会密切合作。设计，开发和未来的商业化将与英国加速器束诊断公司D-Beam Ltd合作进行，该公司是STFC CERN BIC毕业生，最近被确定为STFC IAA的成功案例。商业化计划将与领先的OEM制造商IBA一起推进。JetDose将生产一种新型的监测系统，以满足世界各地医疗设施对体内剂量测定日益增长的需求。这项技术也显示出在其他高强度，高能粒子加速器应用的良好前景，这一更广泛的市场将作为商业计划的一部分进行评估。

In hadron beam therapy, knowledge of the detailed beam properties is essential to ensure effective dose delivery to the patient. Clinical settings currently implement interceptive ionization chambers which require daily calibration and suffer from slow response times. With new and emerging treatment techniques using ultra high dose rates, there is a demand for the development of novel beam monitors, which are fast, non-invasive and calibration-free. Current methods to carry out this characterization require multiple systems each imparting a slight disturbance to the particle beam as it passes by. This disturbance can alter the intended transverse dose profile of the beam, ultimately creating slight deviations from a patient's treatment plan. QA methods are mostly disruptive measurements and do not allow treatment to take place at all whilst they are being conducted.JetDose will develop a new in-vivo dosimetry system based on the re-application of technologies pioneered by the proposer's group. The underpinning technology was originally developed for use with low energy antiproton beams and most recently adapted for gas jet profiling for the high luminosity upgrade of the Large Hadron Collider at CERN. In this system, a supersonic gas jet is fired across the high intensity proton beam at the LHC. The gas molecules have little-to-no effect on the proton beam, however the proton beam excites the gas molecules; this excitation can be imaged, which is turn provides a complete non-invasive two-dimensional profile image of the proton beam. JetDose will redirect this technology at the medical accelerator sector, by optimizing it for the different challenges found in a treatment facility. The non-invasive means of producing a profile image will allow the monitor to be run online alongside treatment operation. As the intensity in the images directly depends upon the beam intensity, and therefore the dose, an image collected with this system provides an in-vivo dose map of the beam being delivered to the patient.The focus of the project will be the design, development, and testing of an optimized medical version of the system with established clinical and business partners. Testing and optimization will be done in close collaboration with long-standing research partners Clatterbridge Cancer Centre and Fondazione CNAO in Italy. The design, development, and future commercialization will be conducted in collaboration with the UK-based accelerator beam diagnostics company D-Beam Ltd, STFC CERN BIC graduate and recently identified as an STFC IAA success story. Commercialization plans will be progressed with leading OEM manufacturer IBA. JetDose will produce a novel monitoring system which addresses the growing need for in-vivo dosimetry in medical facilities across the world. This technology also shows good promise for application at other high intensity, high energy particle accelerators and this wider market will be assessed as part of the business plan that will be developed.